BioMarin's Narrow Moat Supported by Rare Disease Therapies and Developing Pipeline
BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
Zacks.com on MSN8 小时
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and ...
NewsNation6 天
Mother fights to keep insurance to cover son’s life-saving medical food
SEMINOLE, Fla. (WFLA) — A Pinellas County mother is in a desperate fight to keep her 4-year-old son healthy. Gideon Bennett ...